依达拉奉对中度颅脑损伤的疗效评价

目的观察依达拉奉对急性颅脑损伤的治疗效果。方法将78例中度颅脑损伤患者随机分为治疗组和对照组。治疗组在常规治疗的基础上,给予依达拉奉30mg加入生理盐水100ml静脉滴注,30分钟内滴完,每天2次,共用14天,总剂量840mg。记录两组病人治疗前,治疗后第7天、14天、21天的GCS评分及治疗后3个月时的GOS评分。结果治疗后两组病人的GCS评分均有改善,治疗后第一周两组GCS评分无差异,但从第二周开始两组GCS评分即有明显差异;治疗后两组病人3个月时的GOS评分有差异;两组的不良反应无差异。结论依达拉奉对治疗颅脑损伤患者有一定疗效。

Clinical efficacy of edaravone on acute brain injury

Objective To observe the efficacy of edaravone on the treatment of acute brain injury.Methods A total of 78 patients with acute brain injury were divided into observe group and control group randomly.The control group was given a routine treatment of acute brain injury.The observe group was treated with edaravone in addition to the routine treatment.The glasgow coma scale(GCS)in the two groups were recorded before treatment and seven days,14 days,and 21 days after treatment.The glasgow outcome scale(GOS)in the two groups were recorded after three months.Results The GCS of the two groups improved after the treatment.There was no significant difference between the two groups at seven days after treatment.But there was significant difference between the two groups at 14 days after treatment.There was significant difference between the two groups in the GOS after three months.There was no significant difference between the two groups in adverse reaction.Conclusion It is effective to use edaravone in treatment of acute brain injury.